Generalized Cost-Effectiveness Analysis to Assess Treatment

This article estimates the comprehensive value of direct-acting antivirals for the treatment of hepatitis C virus using a generalized cost-effectiveness analysis.

Related Keywords

Canada , United States , Langley , British Columbia , Cuba , Cuban , American , Hepat Mon , Ray Kim , Van Nuys , Jacquelynw Chou , Gastroenterol Hepatol , Health Serv Res , C Value Health , Outcomes Research , Lancet Glob Health , Mark Cuban Cost Plus Drug Company , Appl Health Econ , Security Administration , Bureau Of Economic Analysis , Health Aff Millwood , Precision Medicine Group , Lancet Reg Health , Federal Reserve Bank , Institute For Clinical , Society For Health Economics , Value Health , Bethesda Metro Center , Forum Infect Dis , Professional Society , Health Economics , Generalized Risk Adjusted Cost Effectiveness , Economic Review , Precision Medicine , Metro Center , Task Force , Lancet Gastroenterol , Evid Based , American Association , Mortal Wkly , Health Econ , Forum Infect , Accessed November , Accessed February , Reg Health , Comparative Clinical Effectiveness , Novel Combination Therapies , Patients With Genotype , Thcv , Hepatitis , Cost Effectiveness ,